Jimenez-Zepeda VH

Idioma: Ingles.
Referencias bibliográficas: 4
Paginas: 357-358
Archivo PDF: 91.30 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz- Argüelles GJ. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience. Rev Invest Clin 2012; 64(6, Pt. 2): 604-08.

2. Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, Quint P, et al. Laser Microdissection and Proteomic Analysis of Amyloidosis, Cryoglobulinemic GN, Fibrillary GN, and Immunotactoid Glomerulopathy. Clin J Am Soc Nephrol 2013.

3. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30(36): 4541-9. Doi: 10.1200/JCO.2011.37.7614.

4. Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Sánchez-Cortes E, García-Chávez J, Montiel-Cervantes L, Reyes- Maldonado E, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol 2009; 88(1): 59-66. Doi: 10.1007/s00277-008-0554-0.